. 2004 Oct 30;54(6):587–598. doi: 10.1007/s00262-004-0602-0

Table 3.

Potentiation of antitumor DTH reactivity in immunological responders following vaccination with ATV-NDV. Potentiation of DTH responses to ATV (comparison of last to first reaction), percentage of patients with increases ≥3 mm. PT Primary tumor, LM liver metastasis, n number of patients

	Breast carcinoma	Ovarian carcinoma	Colorectal carcinoma		Renal carcinoma^a	Other tumor types^b
	Breast carcinoma	Ovarian carcinoma	PT	LM	Renal carcinoma^a	Other tumor types^b
Patients (%)	46	39	57	42	35	45
Patients (n)^c	67	18	14	24	20	24

^aIn this tumor type, increased DTH reactions were observed only when the tumor vaccine ATV-NDV was supplemented with IL-2 [53, 54]

^bMelanoma, colon carcinoma, rectal carcinoma, stomach carcinoma, ovarian carcinoma, breast carcinoma, renal cell carcinoma, and acute myeloblastic leukemia [46]

^cIn total, among 264 patients tested, 44% showed increased DTH reactivity to ATV after vaccination